Type and duration of exogenous hormone use affects breast cancer histology

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 695-703

  Kumar, Anjali S ^a,b   Cureton, Elizabeth ^a,b   Shim, Veronica ^a   Sakata, Theadora ^b   Moore, Dan H ^b   Benz, Christopher C ^b,c   Esserman, Laura J ^b   Hwang, E Shelley ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Breast cancer; Estrogen receptor; Hormone replacement therapy

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HISTOLOGY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33846599675     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9129-2     Document Type: Article

References (17)

1. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81:339-44.
2. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92:328-32.
3. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283:485-91.
4. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-93.
5. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Womens Health Study. JAMA 1999; 281:2091-7.
6. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13:1558-68.
7. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev 1993; 15:209-19.
8. Hwang ES, Chew T, Shiboski S, et al. Risk factors for estrogen receptor-positive breast cancer. Arch Surg 2005; 140:58-62.
9. Chen WY, Hankinson SE, Schnitt SJ, et al. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004; 101:1490-500.
10. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289:3254-63.
11. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243-53.
12. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58-66.
13. Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047-59.
14. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999; 281:1528-30.
15. Goss P. Biological characteristics of breast cancer in women who develop breast cancer while receiving HRT. Obstet Gynecol Surv 1998; 53:26S-8S.
16. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a minireview. Hum Reprod 2005; 20:2052-60.
17. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291:2433-40.